[go: up one dir, main page]

WO2004009032A3 - Method and composition for treating and preventing hepatitis b infection and symptoms thereof - Google Patents

Method and composition for treating and preventing hepatitis b infection and symptoms thereof Download PDF

Info

Publication number
WO2004009032A3
WO2004009032A3 PCT/US2003/022961 US0322961W WO2004009032A3 WO 2004009032 A3 WO2004009032 A3 WO 2004009032A3 US 0322961 W US0322961 W US 0322961W WO 2004009032 A3 WO2004009032 A3 WO 2004009032A3
Authority
WO
WIPO (PCT)
Prior art keywords
symptoms
treating
infection
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/022961
Other languages
French (fr)
Other versions
WO2004009032A2 (en
Inventor
Scott Morham
Kenton Zavitz
Adrian Hobden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Priority to AU2003254129A priority Critical patent/AU2003254129A1/en
Publication of WO2004009032A2 publication Critical patent/WO2004009032A2/en
Publication of WO2004009032A3 publication Critical patent/WO2004009032A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods for preventing and treating HBV infection and symptoms thereof by introducing cells displaying a HBV altered budding phenotype into a patient, or by administering to a patient nucleic acids, polypeptides and small organic compounds to cause the formation of cells displaying a HBV altered budding phenotype in the body of the patient.
PCT/US2003/022961 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis b infection and symptoms thereof Ceased WO2004009032A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003254129A AU2003254129A1 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39705402P 2002-07-19 2002-07-19
US60/397,054 2002-07-19
US45302803P 2003-03-07 2003-03-07
US60/453,028 2003-03-07

Publications (2)

Publication Number Publication Date
WO2004009032A2 WO2004009032A2 (en) 2004-01-29
WO2004009032A3 true WO2004009032A3 (en) 2004-10-21

Family

ID=30772984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022961 Ceased WO2004009032A2 (en) 2002-07-19 2003-07-21 Method and composition for treating and preventing hepatitis b infection and symptoms thereof

Country Status (2)

Country Link
AU (1) AU2003254129A1 (en)
WO (1) WO2004009032A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981410B2 (en) * 2006-11-13 2011-07-19 Functional Genetics, Inc. Therapeutic targeting of escort proteins
CN100586474C (en) * 2006-12-28 2010-02-03 北京炎黄麒麟生物技术开发有限公司 Pharmaceutical composition, kit and application thereof
KR100949310B1 (en) * 2007-11-21 2010-03-23 한국과학기술연구원 Method for measuring interaction between HV capsid protein and surface protein using cell imaging technique and detection method of H proliferation inhibitor
US9963751B2 (en) 2015-11-24 2018-05-08 The Penn State Research Foundation Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
CN107254000A (en) * 2017-08-09 2017-10-17 芜湖英特菲尔生物制品产业研究院有限公司 A kind of fusion protein being made up of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of restructuring sheep long-acting interferon γ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARENT L.J. ET AL: "Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins", JOURNAL OF VIROLOGY, vol. 69, no. 9, September 1995 (1995-09-01), pages 5455 - 5460, XP002979975 *

Also Published As

Publication number Publication date
AU2003254129A8 (en) 2004-02-09
AU2003254129A1 (en) 2004-02-09
WO2004009032A2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
WO2003089619A3 (en) Placental derived stem cells and uses thereof
WO2005037214A3 (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
WO2005042703A3 (en) Placental stem cells and uses thereof
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
NO20071912L (en) Donepezil salts suitable for the preparation of pharmaceutical compositions.
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2005095403A3 (en) Macrocyclic compounds as inhibitors of viral replication
PT1782825E (en) Treatment of glycogen storage diseases type ii
WO2005063734A3 (en) Substituted thiophenes
EP1505990A4 (en) METHODS OF TREATING HEPATITIS
WO2006124012A3 (en) Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
WO2003015708A8 (en) Composition and method for treating hiv infection
WO2003059262A3 (en) Method and composition for treating and preventing hiv infection and aids
WO2004009032A3 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2005058934A3 (en) Glycosylated steroid derivatives with anti-migratory activity
WO2004016738A3 (en) Method and composition for treating and preventing hepatitis c infection
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2004009028A3 (en) Method and composition for treating and preventing influenza infection and symptoms thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP